Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis

Anne Harding  |  July 7, 2018

The next steps will be to determine if the bone markers are useful in predicting fracture risk in older men, she added, whether they can predict other types of fracture, and whether they are useful for monitoring people who are stopping their osteoporosis therapy for a drug holiday.

“Those are all very important questions that I think need to be addressed,” she says. “For the time being it doesn’t look like there are clear indications of roles for turnover markers in those settings, but we need to do some methodologically good research to really get solid answers about that.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Crandall CJ, Vasan S, LaCroix A, et al. Bone turnover markers are not associated with hip fracture risk: A case-control study in the Women’s Health Initiative. J Bone Miner Res. 2018 Jul;33(7):1199–1208.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone markersFractureship fracturehip fracture riskOsteoporosis

Related Articles

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug

    January 17, 2018

    NEW YORK (Reuters Health)—Treatment-related changes in bone formation markers predict vertebral-fracture reduction with anti-resorptive drug therapy, according to a meta-regression analysis of 14 clinical trials. “These results may be useful for the development of new osteoporosis treatments or when considering new populations or dosing regimens with existing treatments,” Dr. Douglas C. Bauer from the University…

    Reading Rheum

    March 1, 2007

    Handpicked Reviews of Contemporary Literature

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences